UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 14.660

Sortiert nach

Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer

European journal of cancer (1990), 2016-01, Vol.52, p.1-9

2016

Volltextzugriff (PDF)

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients

Annals of oncology, 2020-07, Vol.31 (7), p.902-911

2020

Volltextzugriff (PDF)

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Annals of oncology, 2019-02, Vol.30 (2), p.281-289

2019

Volltextzugriff (PDF)

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

Annals of oncology, 2017-02, Vol.28 (2), p.292-297

2017

Volltextzugriff (PDF)

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

Annals of oncology, 2022-02, Vol.33 (2), p.169-180

2022

Volltextzugriff (PDF)

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

Annals of oncology, 2020-10, Vol.31 (10), p.1397-1404

2020

Volltextzugriff (PDF)

Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer

Annals of oncology, 2013-08, Vol.24 (8), p.2088-2092

2013

Volltextzugriff (PDF)

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

Annals of oncology, 2018-03, Vol.29 (3), p.687-693

2018

Volltextzugriff (PDF)

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

The New England journal of medicine, 2017-02, Vol.376 (7), p.629-640

2017

Volltextzugriff (PDF)

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Annals of oncology, 2020-04, Vol.31 (4), p.507-516

2020

Volltextzugriff (PDF)

Osimertinib in central nervous system progressive EGFR-mutant lung cancer: do we need to detect T790M?

Annals of oncology, 2020-11, Vol.31 (11), p.1582-1582

2020

Volltextzugriff (PDF)

Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing

Annals of oncology, 2015-01, Vol.26 (1), p.161-166

2015

Volltextzugriff (PDF)

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

Annals of oncology, 2023-03, Vol.34 (3), p.262-274

2023

Volltextzugriff (PDF)

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Annals of oncology, 2015-05, Vol.26 (5), p.894-901

2015

Volltextzugriff (PDF)

Reexamining the Nonlinear Moisture‐Precipitation Relationship Over the Tropical Oceans

Geophysical research letters, 2018-01, Vol.45 (2), p.1133-1140

2018

Volltextzugriff (PDF)

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Annals of oncology, 2020-11, Vol.31 (11), p.1536-1544

2020

Volltextzugriff (PDF)

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Annals of oncology, 2017-04, Vol.28 (4), p.874-881

2017

Volltextzugriff (PDF)

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

Annals of oncology, 2023-03, Vol.34 (3), p.251-261

2023

Volltextzugriff (PDF)

136O Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S115-S115

2016

Volltextzugriff (PDF)

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma

Annals of oncology, 2017-06, Vol.28 (6), p.1250-1259

2017

Volltextzugriff (PDF)

Gas sensing properties of defect-controlled ZnO-nanowire gas sensor

Applied physics letters, 2008-12, Vol.93 (26), p.263103-263103-3

2008

Volltextzugriff (PDF)

A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer

Annals of oncology, 2015-04, Vol.26 (4), p.762-768

2015

Volltextzugriff (PDF)

On-chip fabrication of ZnO-nanowire gas sensor with high gas sensitivity

Sensors and actuators. B, Chemical, 2009-04, Vol.138 (1), p.168-173

2009

Volltextzugriff (PDF)

Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Annals of oncology, 2014-05, Vol.25 (5), p.1044-1052

2014

Volltextzugriff (PDF)

Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial

Annals of oncology, 2019-11, Vol.30 (11), p.1831-1839

2019

Volltextzugriff (PDF)

1 – 25 von 14.660

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(12.751)
Mit Volltextzugriff
(13.324)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(14.252)
Japanisch
(1.885)
Norwegisch
(148)
Koreanisch
(137)
Französisch
(48)
Deutsch
(31)
Russisch
(30)
Portugiesisch
(6)
Spanisch
(6)
Afrikaans
(1)
Dänisch
(1)
Persisch
(1)
Polnisch
(1)
Welsh
(1)

9 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Ingenta
(6.455)
EZB Electronic Journals Library
(5.929)
MEDLINE
(5.589)
Journals@Ovid Complete
(4.117)
Elsevier ScienceDirect Journals Complete
(3.840)
Single Journals
(3.138)
IngentaConnect Journals
(2.630)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(2.486)
Wiley Online Library All Journals
(1.679)
Wiley Online Library Full Collection 2018
(1.190)
Springer journals
(1.015)
IEL
(853)
American Physical Society Journals
(626)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(578)
PROLA - Physical Review Online Archive
(524)
Oxford University Press Journals Current
(445)
Nature
(389)
Ebook Central Perpetual and DDA
(364)
eBooks on EBSCOhost
(363)
Taylor & Francis Journals
(306)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Physical Review Letters
(342)
Annals Of Oncology
(326)
Physics Letters. B
(173)
Journal Of Clinical Oncology
(161)
The Journal Of Biological Chemistry
(125)
Cancer Research
(123)
Journal Of Thoracic Oncology
(123)
The Spine Journal
(107)
Blood
(104)
Journal Of Korean Medical Science
(103)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Osimertinib in central nervous system progressive EGFR-mutant lung cancer: do we need to detect T790M?

Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Reexamining the Nonlinear Moisture‐Precipitation Relationship Over the Tropical Oceans

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

136O Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma

Gas sensing properties of defect-controlled ZnO-nanowire gas sensor

A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer

On-chip fabrication of ZnO-nanowire gas sensor with high gas sensitivity

Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial

Suchergebnisse filtern